DURAGESIC-100
Clinical safety rating
cautionComprehensive clinical and safety monograph for DURAGESIC-100 (DURAGESIC-100).
Pure opioid agonist that binds to mu-opioid receptors in the CNS, mimicking endogenous endorphins to inhibit pain transmission. Also interacts with kappa and delta receptors. Therapeutic effects include analgesia, sedation, and euphoria.
| Metabolism | Primarily metabolized by CYP3A4 isoenzyme to norfentanyl and other inactive metabolites. Minor pathways via CYP3A5. First-pass metabolism is extensive after oral administration, but transdermal delivery bypasses this. |
| Excretion | Renal (primarily as metabolites, <10% unchanged fentanyl); fecal (about 9% of dose). |
| Half-life | Terminal elimination half-life approximately 20–27 hours after transdermal system removal (range 13–25 hours in healthy adults; prolonged in elderly, hepatic impairment, and cachexia). |
| Protein binding | Approximately 80–85% bound, primarily to alpha-1-acid glycoprotein (AAG) and albumin; increased free fraction in hypoalbuminemia. |
| Volume of Distribution | 3–8 L/kg (mean ~6 L/kg), indicating extensive tissue distribution (including deep compartments such as muscle and fat). |
| Bioavailability | Transdermal: approximately 92% of the dose over 72 hours (systemic absorption fraction). |
| Onset of Action | Transdermal: 12–24 hours for initial therapeutic effect (steady-state reached by 24–72 hours with continuous wear). |
| Duration of Action | 72 hours after application, with analgesic effect persisting for 12–24 hours after system removal due to residual drug in skin depot. |
| Molecular Weight | 336.47 |
Transdermal patch; initial dose based on prior opioid use: for opioid-naive patients, 12 mcg/h every 72 hours; for opioid-tolerant patients, convert using equianalgesic tables; maximum dose 100 mcg/h per patch; apply to non-irritated, non-irradiated skin on chest, back, flank, or upper arm.
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | GFR 30-60 mL/min: no adjustment required; GFR <30 mL/min: reduce dose by 50% and titrate cautiously; hemodialysis: not removed, avoid use or use with extreme caution. |
| Liver impairment | Child-Pugh class A: no adjustment; Child-Pugh class B: reduce initial dose by 50% and titrate slowly; Child-Pugh class C: avoid use or reduce dose by 75% with careful monitoring. |
| Pediatric use | For children ≥2 years old: initial dose 25 mcg/h for opioid-tolerant patients; for opioid-naive, use alternative analgesic; titrate in 12-25 mcg/h increments every 72 hours; do not use in children <2 years. |
| Geriatric use | Start at lowest available strength (12 mcg/h) and titrate slowly; monitor for respiratory depression, constipation, and cognitive effects; consider increased sensitivity to opioid effects. |
| 1st trimester | FDA Pregnancy Category C. Fentanyl crosses placenta. Use only if benefit outweighs risk; may cause fetal dependence. |
| 2nd trimester | Same as T1; prolonged use may lead to neonatal withdrawal syndrome. |
| 3rd trimester | Risk of respiratory depression in newborn; avoid near term or during labor. |
Clinical note
Comprehensive clinical and safety monograph for DURAGESIC-100 (DURAGESIC-100).
| Placental transfer | Fentanyl readily crosses the placenta; umbilical vein concentrations are approximately 50% of maternal plasma levels. |
| Breastfeeding | Fentanyl enters breast milk in low concentrations (milk:plasma ratio ~0.4). Use with caution; monitor infant for respiratory depression, sedation, and withdrawal. Short-term use is likely compatible according to AAP. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Data insufficient to establish specific risk; fentanyl crosses placenta. Second/third trimester: Chronic use may cause neonatal opioid withdrawal syndrome (NOWS). Use not recommended unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal respiratory status, sedation, and signs of withdrawal. Fetal monitoring for heart rate variability and growth; assess for NOWS postpartum. |
| Fertility Effects | Chronic opioid use may cause hypogonadism, leading to menstrual irregularities and reduced fertility in females; in males, decreased libido and spermatogenesis. |
■ FDA Black Box Warning
Risk of respiratory depression, especially in non-opioid-tolerant patients; risk of accidental exposure leading to fatal overdose; contraindicated in acute or postoperative pain; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of interaction with CYP3A4 inhibitors leading to fatal respiratory depression; risk of death from concomitant use with benzodiazepines or CNS depressants.
| Serious Effects |
Hypersensitivity to fentanyl or any transdermal system componentAcute or postoperative pain (not indicated)Severe respiratory depression (especially in non-opioid-tolerant patients)Concurrent use of MAOIs or within 14 days of discontinuation
| Precautions | Life-threatening respiratory depression: monitor closely, especially during initiation and dose escalation, Accidental exposure: can cause fatal overdose in children; apply patch to dry, non-irritated skin on flat surface of upper torso, Neonatal opioid withdrawal syndrome: prolonged use during pregnancy can result in withdrawal in newborns, Risks from concomitant use with benzodiazepines or CNS depressants: additive sedation and respiratory depression, Risk of hypotension, bradycardia, and seizure in patients with compromised cardiovascular or cerebrovascular function, Serotonin syndrome when co-administered with serotonergic drugs, Adrenal insufficiency and androgen deficiency with long-term use, Severe hypotension in patients with reduced blood volume or concurrent drug therapy that compromises vasomotor tone, Biliary tract spasm and increased intracholedochal pressure, Avoid in patients with head injury, increased intracranial pressure, or impaired consciousness, Do not cut, chew, or swallow patch; apply patch immediately after removal from package; wear time 72 hours, Fever or external heat can increase absorption; avoid exposing application site to direct heat sources |
| Food/Dietary | Avoid grapefruit and grapefruit juice during therapy, as they can affect liver enzymes and alter fentanyl metabolism. No other specific food restrictions. However, a high-fat meal may delay absorption of oral fentanyl but this is not relevant for transdermal formulation. Maintain caution with alcohol intake as it can potentiate CNS depression. |
| Clinical Pearls | Duragesic-100 is a transdermal fentanyl patch delivering 100 mcg/h. Use only in opioid-tolerant patients due to risk of respiratory depression. Do not cut or damage the patch; apply to non-irritated, non-hairy skin on upper torso. Avoid heat sources (heating pads, saunas) as increased temperature can accelerate drug absorption, leading to fatal overdose. Monitor for signs of serotonin syndrome when co-administered with serotonergic drugs. Rotate application sites to minimize skin irritation. |
| Patient Advice | Apply the patch to clean, dry, hairless skin on the chest, back, or upper arm. Do not shave the area; clip hair if necessary. · Do not cut, tear, or damage the patch. Use only as directed by your healthcare provider. · Avoid exposing the patch to direct heat sources such as heating pads, electric blankets, hot tubs, or prolonged sunbathing, as this can increase the amount of medicine absorbed and cause a fatal overdose. · Keep the patch away from children and pets, as exposure can be fatal. Dispose of used patches by folding them in half and flushing down the toilet or placing in a sealed container. · Do not stop using this medication suddenly without consulting your doctor, as withdrawal symptoms may occur. · Seek emergency help if you experience slow/shallow breathing, difficulty waking up, or extreme drowsiness. · Do not drink alcohol while using this medication, as it may increase the risk of serious side effects. |
Loading safety data…